tetano
Editor, Senior Moderator
Am J Transplant. 2016 Jul 12. doi: 10.1111/ajt.13960. [Epub ahead of print]
[h=1]Heterologous Immune Responses to Influenza Vaccine in Kidney Transplant Recipients.[/h] Kumar D[SUP]1[/SUP], Ferreira VH[SUP]1[/SUP], Campbell P[SUP]2[/SUP], Hoschler K[SUP]3[/SUP], Humar A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza vaccine is known to have suboptimal immunogenicity in transplant recipients. Despite this, influenza vaccine may have the added benefit of inducing a cross-reactive immune response to viral strains not found in the vaccine. This is termed heterologous immunity and has not been previously assessed in transplant patients. Pre- and post-vaccination sera from kidney transplant recipients (n=60) immunized with the 2012-13 adjuvanted or nonadjuvanted influenza vaccine underwent testing by hemagglutination inhibition assay for strains not present in vaccine: A/New Caledonia/20/99 (H1N1), A/Texas/50/2012 (H3N2), B/Brisbane/60/2008. The geometric mean titer of antibody to heterologous strains increased after vaccine (H1N1: 80.0 to 136.1, p<0.001; H3N2: 23.3 to 77.3, p<0.001; B: 13.3 to 19.5, p<0.001). Seroconversion rates were 16.7%, 41.7%, and 13.3% respectively. No differences in heterologous response were seen in the adjuvanted vs. nonadjuvanted groups. Patients were more likely to seroconvert for a cross-reactive antigen if they seroconverted for the specific vaccine antigen. For example, seroconversion to heterologous-A/H3N2 was 84.0% for homologous H3N2 seroconverters vs. 11.4% for non-seroconverters, p<0.001. This study provides novel evidence that transplant recipients are able to mount significant cross-protective responses to influenza vaccine which may be an additional, previously unknown, benefit of immunization. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Immunogenicity; Immunosuppression; Serology; cross-protection
PMID: 27402204 DOI: 10.1111/ajt.13960
[PubMed - as supplied by publisher]
[h=1]Heterologous Immune Responses to Influenza Vaccine in Kidney Transplant Recipients.[/h] Kumar D[SUP]1[/SUP], Ferreira VH[SUP]1[/SUP], Campbell P[SUP]2[/SUP], Hoschler K[SUP]3[/SUP], Humar A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza vaccine is known to have suboptimal immunogenicity in transplant recipients. Despite this, influenza vaccine may have the added benefit of inducing a cross-reactive immune response to viral strains not found in the vaccine. This is termed heterologous immunity and has not been previously assessed in transplant patients. Pre- and post-vaccination sera from kidney transplant recipients (n=60) immunized with the 2012-13 adjuvanted or nonadjuvanted influenza vaccine underwent testing by hemagglutination inhibition assay for strains not present in vaccine: A/New Caledonia/20/99 (H1N1), A/Texas/50/2012 (H3N2), B/Brisbane/60/2008. The geometric mean titer of antibody to heterologous strains increased after vaccine (H1N1: 80.0 to 136.1, p<0.001; H3N2: 23.3 to 77.3, p<0.001; B: 13.3 to 19.5, p<0.001). Seroconversion rates were 16.7%, 41.7%, and 13.3% respectively. No differences in heterologous response were seen in the adjuvanted vs. nonadjuvanted groups. Patients were more likely to seroconvert for a cross-reactive antigen if they seroconverted for the specific vaccine antigen. For example, seroconversion to heterologous-A/H3N2 was 84.0% for homologous H3N2 seroconverters vs. 11.4% for non-seroconverters, p<0.001. This study provides novel evidence that transplant recipients are able to mount significant cross-protective responses to influenza vaccine which may be an additional, previously unknown, benefit of immunization. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Immunogenicity; Immunosuppression; Serology; cross-protection
PMID: 27402204 DOI: 10.1111/ajt.13960
[PubMed - as supplied by publisher]